Brooks D. Cash

Brooks D. Cash

Auto-generated profile, based on publicly available information

Brooks D. Cash

Department of Internal Medicine, McGovern School of Medicine, University of Texas Health Science Center at Houston, Houston, Texas, United States of America

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2015 in Digestive Diseases and Sciences
Verified
Journal Article
Open access
PDF file
BCBrooks D. Cash
Brooks D. Cash
MEMichael S. Epstein
Michael S. Epstein
SSSyed M. Shah
Syed M. Shah
Background Peppermint oil (PO) has shown promise as an IBS therapy, but previous trials have demonstrated variable efficacy and tolerability results. Aims To evaluate the efficacy and tolerability of a novel formulation of PO designed for sustained release in the small intestine in patients with IBS-M and IBS-D. Methods This is a 4-week, randomized, double-blind, placebo-controlled clinical trial of PO or identical placebo 3 times daily in patients fulfilling Rome III criteria for IBS-M or IBS-D. The primary endpoint was the change from baseline in the Total IBS Symptom Score (TISS) after 4 weeks of treatment. Results Seventy-two patients (mean age 40.7 years, 75 % female, 77.8 % white) were randomized to PO (n = 35) or placebo (n = 37). At 4 weeks, PO was associated with a 40 % reduction in the TISS from baseline (mean change −1.16, SD ± 0.807), superior to the 24.3 % decrease (mean change −0.70, SD ± 0.737) observed with placebo (P = 0.0246). The decrease in the TISS of 19.6 % (mean change −0.55, SD ± 0.613) in the PO group at 24 h was also significantly larger than placebo (−10.3 %, mean change −0.27, SD ± 0.342) (P = 0.0092). At trial completion, patients in the PO group experienced greater improvement in multiple individual gastrointestinal symptoms as well as in severe or unbearable symptoms, compared to placebo. PO was well tolerated with few adverse events. Conclusions A novel PO formulation designed for sustained release in the small intestine is a safe, effective treatment capable of providing rapid relief of IBS symptoms.

1 April 2018 in Gastroenterology
Verified
Journal Article
Closed access
SPSravanthi Parasa
Sravanthi Parasa
SVSreekar Vennalaganti
Sreekar Vennalaganti
SGSrinivas Gaddam
Srinivas Gaddam
PVPrashanth Vennalaganti
Prashanth Vennalaganti
PYPatrick Young
Patrick Young
PSPrateek Sharma
Prateek Sharma

1 February 2017 in American Journal of Gastroenterology
Verified
Journal Article
Open access
BCBrooks D Cash
Brooks D Cash
BLBrian E Lacy
Brian E Lacy
PSPhilip S Schoenfeld
Philip S Schoenfeld
LDLeonard S Dove
Leonard S Dove
PCPaul S Covington
Paul S Covington
Objectives: Methods: Results: Conclusions:

1 February 2018
Verified
Journal Article
Closed access
BNBenjamin Niland
Benjamin Niland
BCBrooks D Cash
Brooks D Cash

18 December 2020 in Gut
Verified
Journal Article
Closed access
PDF file
BCBrooks D Cash
Brooks D Cash
MFMark R Fleisher
Mark R Fleisher
SFSteven Fern
Steven Fern
ERElizabeth Rajan
Elizabeth Rajan
RHRobyn Haithcock
Robyn Haithcock
DRDouglas K Rex
Douglas K Rex
Objective Colon capsule endoscopy (CCE) has shown promise for colorectal neoplasia detection compared with optical colonoscopy (OC), but has not been compared with other screening tests in average risk screening patients. Design Patients 50 to 75 years of age (African Americans, 45–75 years) were randomised to CCE or CT colonography (CTC) and subsequent blinded OC. The primary endpoint was diagnostic yield of polyps ≥6 mm with CCE or CTC. Secondary endpoints included accuracy for size and histology, examination completeness, number/proportion of subjects with polyps and adenomas ≥6 mm and ≥10 mm, subject satisfaction and safety. Results From 320 enrolled subjects, data from 286 (89.4%) were evaluable. The proportion of subjects with any polyp ≥6 mm confirmed by OC was 31.6% for CCE versus 8.6% for CTC (pPr non-inferiority and superiority=0.999). The diagnostic yield of polyps ≥10 mm was 13.5% with CCE versus 6.3% with CTC (pPr non-inferiority=0.9954). The sensitivity and specificity of CCE for polyps ≥6 mm was 79.2% and 96.3% while that of CTC was 26.8% and 98.9%. The sensitivity and specificity of CCE for polyps ≥10 mm was 85.7% and 98.2% compared with 50% and 99.1% for CTC. Both tests were well tolerated/safe. Conclusion CCE was superior to CTC for detection of polyps ≥6 mm and non-inferior for identification of polyps ≥10 mm. CCE should be considered comparable or superior to CTC as a colorectal neoplasia screening test, although neither test is as effective as OC. Trial registration number ClinicalTrials.gov no: NCT02754661.

8 October 2015 in Current Gastroenterology Reports
Verified
Journal Article
Closed access
PDF file
HSHani Sbahi
Hani Sbahi
BCBrooks D. Cash
Brooks D. Cash